2024-01-14 05:25:57
OCI, Hanmi Pharmaceutical
The possibility of a management dispute has increased over the integration of energy and chemical company OCI Group and new drug development company Hanmi Pharmaceutical Group. Previously, OCI Group’s holding company, OCI Holdings, and Hanmi Science (Hanmi Pharmaceutical Group’s holding company) announced that they would create an integrated holding company and begin integration, but conflict erupted as the eldest and second sons of the late Lim Seong-gi, the founder of Hanmi Pharmaceutical, protested. .
According to the business world on the 14th, Lim Jong-yoon, the eldest son of the late founder Lim Seong-gi and CEO of Hanmi Pharmaceutical’s Future Strategy, posted on the “We have not received any information or materials,” he said, adding, “We will express our official position following carefully and comprehensively understanding the current situation.”
Previously, OCI Holdings, the holding company of OCI Group, announced that it would acquire approximately 27% of the shares (KRW 770.3 billion) of Hanmi Science, and at the same time, major shareholders of Hanmi Science, including Lim Joo-hyun, director of Hanmi Science, the eldest daughter of founder Lim, would acquire approximately 10.4% of the shares of OCI Holdings. Once the stake acquisition of both parties is completed, OCI Holdings will become the largest shareholder of Hanmi Science, and Director Lim Joo-hyeon will become the largest individual shareholder of OCI Holdings (10.37%).
President Lim Jong-yoon, the eldest son who opposed this integration between the two companies, is a major shareholder with a 9.91% stake in Hanmi Science. The second son, Lim Jong-hoon, CEO of Hanmi Pharmaceuticals, who is said to share the same interests as the eldest son, President Lim, holds a 10.56% stake in Hanmi Science, which amounts to 20% when the two brothers’ shares are added together.
The shares of Chairman Song Young-sook and Director Lim, who led the overall management of Hanmi Pharmaceutical Group and led this integration, are 11.66% and 10.2%, respectively. A pharmaceutical industry official said, “It appears that the eldest son and second son are opposed, but it is expected that it will be difficult to reverse the integration between the two companies that was decided through the board of directors.”
1705228479
#Mother #daughter #eldest #son #son.. #Hanmi #Pharmaceutical #management #rights #dispute #OCI #integration
